Skip to content

Glaukos GKOS Total Liabilities

Total Liabilities at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$119.71B+3.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$9.45B+15.8%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$4.24B+2.9%
Exelixis logo
ExelixisEXEL
$657.85M-6.9%
Boston Scientific logo
Boston ScientificBSX

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's total liabilities?
Glaukos (GKOS) reported total liabilities of $222.4M in Q1 2026.
How has Glaukos's total liabilities changed year-over-year?
Glaukos's total liabilities increased by 10.0% year-over-year, from $202.22M to $222.4M.
What is the long-term trend for Glaukos's total liabilities?
Over 5 years (2020 to 2025), Glaukos's total liabilities has grown at a -6.8% compound annual growth rate (CAGR), from $338.05M to $237.33M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.